LIXTE Biotech Reports 2025 Progress: Clinical Trials Expand, Acquisitions Boost Oncology Platform
April 1, 2026 — LIXTE Biotechnology files 2025 annual report, highlighting clinical progress with LB-100 cancer drug, acquisition of Liora Technologies, and $11M funding for oncology innovation.